279 results about "Histocompatibility" patented technology

Cell-based compositions and methods of their use to inhibit an adverse immune response such as graft versus host disease or rejection of transplanted tissue in a transplant recipient that is histocompatibility mismatched to the transplant donor are disclosed. The compositions and methods utilize postpartum-derived cells, such as cells derived from the placenta or umbilicus.

The subject invention pertains to materials and methods for preparing multi-potential stem cells having a pre-selected expression of MHC antigens. Stem cells of the subject invention can be used to generate histocompatible tissues/organs for transplantation. The process of the subject invention comprises the use of targeting vectors capable of gene knockout, insertion of site-specific recombination cassettes, and the replacement of histocompatibility alleles in the stem cell. Novel knockout vectors are used to delete designated regions of one chromosome. Recombination cassette vectors are then used to delete the same region on the second chromosome and deposit a site-specific recombination cassette which can be utilized by replacement vectors for inserting the new MHC genes on the chromosome of the engineered cell. The subject invention also pertains to cells, tissues, and transgenic mammal prepared using the methods and materials of the invention.

The invention relates to a guided tissue regeneration membrane, which comprises a compact coating and a loose coating, wherein the compact coating is composed of collagen-I or collagen-I composite hyaluronic acid; and the loose coating is composed of collagen-I or collagen-I composite calcium salt. A preparation method of the guided tissue regeneration membrane comprises the following steps of: preparing a collagen solution or a collagen and hyaluronic acid mixed solution by the use of acetic acid; injecting the solution into a self-made die, and drying it in the air to prepare the compact coating; injecting the collagen solution or a mixed liquor of the collagen solution and calcium salt onto the compact coating, and uniformly spreading; precooling the die at ultralow temperature, followed by freeze-drying to prepare the guided membrane with the compact coating and loose coating structure; carrying out vacuum high-temperature crosslinking and chemical crosslinking; and finally cleaning. The regeneration membrane has good histocompatibility and mechanical strength, low antigenicity and strong guided tissue regeneration capability. Its degradation rate in vivo is 3-8 months. The method is easy to operate, is suitable for automatic and continuous large-scale production, and solves the problems of large size of collagen membrane and material uniformity during industrial production.

The invention provides a duodenal internal covering membrane, which is made of degradable shape memory biocompatible material and relates to degradable medical equipment internally installed in a digestive tract. After the internal covering membrane is implanted into a duodenum, chyme can be split from bile and pancreatic juice, so stomach exudates are prevented from being directly digested, absorbed and metabolized in the duodenum, and the histocompatibility is good; after being implanted into a human body, the duodenal internal covering membrane is steady, is not easy to slide off to be incarcerated and can be gradually degraded in the human body after 2 months to 5 years, so complicated operation and the injury to organs and tissue, which are caused when the duodenal internal covering membrane is removed from the human body in the future, are avoided, a rebound effect achieved after the original barrier is instantaneously and thoroughly dismounted can be slowed down, and the duodenal internal covering membrane can be prepared into medical equipment which is used for curing obesity and diabetes mellitus and does not need to be removed from the human body in the future; and tube-shaped part sinking induced by gastrointestinal motility and jejunum content backflow caused by the decrease of a gap between a tube-shaped part of the internal covering membrane and the inner wall of the duodenum can be avoided. The prepared medical equipment for curing the obesity and the diabetes mellitus can achieve the effects of dropping prevention, removal exemption, rebound inhibition and injury reduction.

The invention discloses an alkyl modified chitosan/mesoporous silicon dioxide composite quick hemostatic powder and a preparation method thereof. The method comprises the following steps: 1) preparation of alkyl modified chitosan; 2) preparation of mesoporous silicon dioxide particles; and 3) preparation of composite quick hemostatic powder: dissolving the alkyl modified chitosan in an acetic acid water solution, adding polyethyleneglycol 20000 to be dissolved, adding the mesoporous silicon dioxide particles prepared in the step 2), stirring at room temperature, freeze-drying the precipitate, suspending the precipitate in dimethylsulfoxide, regulating the pH value, centrifuging, washing with deionized water, and freeze-drying to obtain the alkyl modified chitosan/mesoporous silicon dioxide composite quick hemostatic powder. The hemostatic powder disclosed by the invention can quickly stop bleeding, and is suitable for pre-hospital emergency treatment of severe bleeding wounded persons. The material has the advantages of high hemostatic speed, excellent hemostatic effect, favorable biocompatibility and histocompatibility, and no side effect.

The invention relates to a preparation method of an anti-adhesion absorbable hernia patch. The preparation method adopts a two-step spinning method and includes first degrading a polycaprolactone (PCL) fiber layer with long period as a support base layer in electrospinning mode, then degrading a poly lactic-co-glycolic acid (PLGA) fibrous membrane as a function layer in electrospinning mode and reasonably selecting a solvent in the PLGA electrospinning process to obtain a double-layer fibrous membrane material with a double-layer fibrous membrane firmly. The fibrous membrane material prepared by the method combines excellent dynamic performance of PCL and histocompatibility of PLGA and can be widely used in the hernia repair technology.

The invention relates to a preparation method for a nanometer graphene carrier used for an MRI contrast agent. According to the method, nanometer graphene oxide and hydrophilic high polymers are used as raw materials; the hydrophilic high polymers are grafted onto the surface of nanometer graphene oxide, and a contrast agent is loaded wherein. Compared to the prior art, the invention has the following advantages: by utilizing good hydrophilicity and biocompatibility of some hydrophilic high polymers and the characteristic that the system of nanometer graphene oxide and hydrophilic high polymers can enter into biological cells at a nanometer level, the contrast agent is enabled to have long in-vivo retention time, good histocompatibility and low cytotoxicity; the system shows a good application prospect in the aspect of MRI radiography.

The invention relates to a medical degradable and absorbable Mg-Sr-Ca series magnesium alloy implant and a preparation method thereof. The medical implant is made of a Mg-Sr-Ca series alloy, wherein strontium is 0 to 5 percent (but not 0) of the weight of the Mg-Sr-Ca series alloy; calcium is 0 to 2 percent (but not 0) of the weight of the Mg-Sr-Ca series alloy; a small amount of one or more of trace elements, namely manganese, zirconium, tin, rare earth and yttrium may be contained, and are not more than 2 percent of weight of the Mg-Sr-Ca series alloy; and the balance is magnesium. In-vivo and in-vitro tests prove that the Mg-Sr-Ca series alloy implant is nontoxic, has high histocompatibility, and is a reliable biomedical implant material.

The invention discloses a high-plasticity and biodegradable Zn-Mn-system zinc alloy and a preparation method thereof and belongs to the technical field of biomedical metallic material composition design and preparation. The zinc alloy is prepared from 0.1%-3% by mass of Mn and the balance Zn. The zinc alloy has the good mechanical properties after vacuum induction melting and plastic working and meets the requirements for strength and plasticity of medical implant materials. The zinc alloy is non-toxic and degradable in vivo and has the good histocompatibility and blood compatibility, and dissolved metal ions can be absorbed and utilized by organisms for promotion of repair of tissue and organs or can be excreted to the outside of the body through metabolism.

The invention discloses a chitosan hydrogel. The structural unit of the chitosan hydrogel is shown in the specification; and in the structural unit, m is a natural number in a range of 400-700, and n is a natural number in a range of 30-100. The invention also discloses a preparation method of the chitosan hydrogel, and an application of the chitosan hydrogel. The method comprises the following steps: polyethylene glycol and tyramine molecules are grafted to a chitosan molecular chain in order to obtain a highly-water-soluble chitosan derivative, and the derivative is processed under the action of a crosslinking reagent to obtain the chitosan hydrogel. The process of the preparation method is simple, and the prepared chitosan hydrogel has the advantages of good physical, chemical and biological performances, good histocompatibility, environmental protection, and non-toxicity, and can be safely and effectively applied in restoration of wound tissues.

PURPOSE: Provided are a method and a substance useful for treatment and diagnosis of prostate cancer. Particularly, provided are a peptide having a specific sequence, a mutant thereof and a nucleic acid encoding the same. CONSTITUTION: An HLA-A24- restricted antigen peptide is characterized by being capable of inducing a CTL(cytotoxic lymphocyte) having a T cell receptor specifically recognizing a cell manifesting on the cell surface a complex between the peptide and HLA(human main histocompatibility antigen)-A24 molecule.

Disclosed is a method for surface modification of an artificial implant with covalent cross-linked gel to make same of good blood compatibility and histocompatibility, comprising a.alternately depositing polyanions and polycations on artificial implant surface via electrostatic attraction; b.preparing carboxyl acid group polymer solution or mixing solution thereof with biologically active substance, coating said solution on artificial implant surface, adding appropriate amount of polyamine and cross-linking with [1-ethyl-3-(3-dimethylamino-propyl)]-carbodiimide(EDC); c.rinsing the artificial implant with a mixing solution of CaCl2(or BaCl2) and other inorganic salts, washing same with water, and drying same.

The invention relates to a method for preparing the conspecific allo vessel de-cell support, which comprises that using the abdominal aorta of rabbit of New Zealand, using surface activator Triton X-100 to extract the liposome of cell membrane, and digesting the parenzyme, using nuclease DNAse and RNAse to degrade the DNA and RNA of cell, to obtain the support. The invention uses the similar structures of conspecific allo materials, with better histocompatibility, to support healing after surgery, with simple preparation and high efficiency. And the invention can be transplanted with low caused immunity reaction of host, to supply physical strength and tension. The invention can be used to replace blood vessel.

The invention discloses a risperidone nano-suspension temperature sensitive gel and its preparation method. Each 100ml of the nanosuspension temperature sensitive gel contains 0.1-10g of risperidone, 0.1-5g of a stabilizer, 1-50g of a temperature sensitive gel material, 0-5g of an additive, and the balance of a water-based solvent. The risperidone nano-suspension temperature sensitive gel is a temperature sensitive controlled-release in situ gel. The above dosage form makes risperidone highly dispersed, so the gel has the advantages of good drug load and good stability; after the gel is administrated in a liquid form, phase transition occurs in applied sites, and the liquid becomes non-chemically-crosslinked semisolid gel, so the gel has good histocompatibility and improves the drug dissolution rate; and the administrated gel has a long retention time in the applied sites as a drug reservoir, so the gel has a slow release effect, prolongs the drug release time, improves the drug bioavailability, reduces the administration frequency and improves the drug effect and the patient compliance.

The invention discloses an HLA (histocompatibility locus antigen) genetic typing method of an HLA determinant gene through high-throughput sequencing. Patterning HLA typing software based on various high-throughput sequencing platform data has important significance in clinic or biomedicine. Compared with the traditional sequencing method through a PCR-SBT (polymerase chain reaction-sequence based typing) method, the high-throughput sequencing technology has the obvious advantages in economic cost and time cost. HLA sequence data of thousands of samples can be read through an experiment and high resolution of HLA typing is achieved at one time through the high-throughput sequencing technology, and meanwhile, a new allele can be found. Qualitative leap in the aspects of flux detection, data quality, cost control and the like are achieved, 'low cost and high data' are achieved, additional economic burden of a patient caused by typing for multiple times can be avoided, the time for searching for a provider whose HLA is matched with that of the patient can also be reduced, and the precious time is saved for treating the patient.

The invention relates to a chitosan biofilm polypropylene mesh and a preparation method thereof. According to the invention, a polypropylene mesh is processed by using waterless ethanol and deionized water; the polypropylene mesh is modified by using 1.0 to 5.0% of a chitosan film forming solution through a process of biofilm forming, such that a chitosan biofilm polypropylene mesh is obtained. The method of the invention is simple and operable. No toxic or harmful reagent is included. No adverse effect is brought to subsequent applications of the medical mesh. According to the invention, the polypropylene mesh has a high porosity, peripheral tissue can well contact and grow on the polypropylene mesh, such that the anti-stretching property of a repaired part is enhanced; also, chitosan has a good biocompatibility, such that complications such as polypropylene mesh erosion, exposure and tissue adhesion at an implantation position are effectively reduced. The chitosan biofilm polypropylene mesh is especially suitable for clinical women pelvic reconstructive surgery. With the chitosan biofilm polypropylene mesh, histocompatibility of the polypropylene materials in pelvic reconstructive operations is improved, and pelvic reconstruction postoperative complications are reduced.

The invention relates to the technical field of medical appliances, in particular to a support type artificial venous blood vessel with valve for treating venous reflux diseases and venous return obstruction diseases. The artificial venous blood vessel comprises artificial valve (1) inside the artificial blood vessel, a metal support (2) attached to the outer wall of the artificial blood vessel to support the artificial blood vessel, a metal ring (3) attached to the metal support to support the valve and an artificial blood vessel (4) beyond the range of the support. The artificial venous blood vessel is produced according to the normal vessel valve structure of the human body, the vessel valve can be opened and closed freely, the supporting strength of the support is proper, and the supporting metal ring can maintain the normal state of the vessel valve. The artificial venous blood vessel has the advantages of reasonable structure, low fabrication cost and good histocompatibility, and can be used for valve repair operation for lower limb deep vein, valve repair operation for upper limb deep vein and main vein return obstruction disease of four limbs (especially occlusive diseases) After the vein of the pathologic section is resected, the support type artificial venous blood vessel with the valve is stitched on the normal vein, the operation is simple, and the operative wound is small.

Marker compounds indicative of variations in physiological conditions, genetic defects or disease states have been found to be present in apocrine sweat and, in many conditions, these markers are present in apocrine sweat in elevated levels when compared to blood. These markers are collected and/or detected in apocrine sweat and used as an indicator that a disease state or particular physiological condition exists. A skin patch, wipe or electronic detector for vapors released from apocrine sweat are used to indicate the existence of a disease state or changing physiological condition. The patch or wipe can include in monoclonal antibodies or other chemical compounds that can indicate the presence of specific markers. This may include indicators that render visible, the existence of a reaction between the monoclonal antibody or chemical compound and the marker compound to indicate the existence of the condition being tested for. Various different disease states can be detected including, but not limited to heart disease, cancer, autoimmune disease, viral or bacterial disease, renal disease, drug intoxication and other systemic illnesses. Fertility for conception and histocompatibility for organ transplantation of individuals should also be detectable.

The invention discloses a preparation method of a xenogenic acellular dermal matrix. The method specifically includes the following steps of taking dermis, removing epidermal layers, conducting acellular disposal, punching holes through lasers, and conducting sterilizing. By means of the method, cell components are removed thoroughly, antigenicity is low, the dermal collagen structure is kept, histocompatibility is high, the time of the whole preparation process is only about 60 hours, disposal time is short, disposal cost is low, and good social benefits and economic benefits are achieved.

The invention discloses a method for grafting 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer on a titanium-base material surface. A layer of middle bridging groups, namely organic phosphate or phosphate monoester which respectively forms chemical bonding with the titanium-base material surface and the MPC polymer is prepared on the titanium-base material surface and the MPC polymer by a self-assembled monolayer method; and the MPC polymer is grafted on the titanium-base material surface by a surface-initiated atom transfer radical polymerization method. In the prepared simulative functionalized titanium-base material of the method, the MPC polymer on the surface of the simulative functionalized titanium-base material has strong bonding force with the titanium-base material and has better histocompatibility and better blood compatibility. The invention has simple process and is easy to realize.

The invention discloses an anti-blocking liquid used in surgery and a method for preparing the same. The anti-blocking liquid comprises 1 weight% carboxymethyl chitosan having molecular weight of 200000-300000 dalton and 30-100 weight% water for injection, which dynamics viscosity is 100~800 centipoise. The preparing method comprises: removing impurity protein pyrogen from the raw material; carboxymethyl-modification of chitin; purifying the carboxymethyl chitosan; preparing the anti-blocking liquid and the preparation thereof. Accordingly, the anti-blocking liquid has excellent biological barrier performance and histocompatibility, after applied on tissue wound surface, can prevent tissue tissue adhesion postoperation, which intermediary metabolite and final metabolite in human body are normal metabolites facilitating to be absorbed by the human body, without toxicity and acrimony. The anti-blocking liquid has abundance material sources with low cost and simple process, thus has broad application prospects in clinical medicine art.

The invention discloses a processing method for functionalization modification on biomedical titanium alloy surface, and active hydroxide radical, amidogen and carboxyl are introduced to the medical titanium alloy surface by the treatment of hydroxylation solution and amidogen solution. The process is as follows: the biomedical titanium alloy sample is firstly treated in hydrogen peroxide containing little Fe<2+> and hydrochloric acid solution, then is placed into polyacrylamide solution in nitrogen atmosphere, a suitable amount of cerous nitrate salt is added, hypochlorite solution is added after reaction for a time, the reaction is continued, and the sample is rinsed and air-dried in NaOH solution and hot water sequentially after cooling. Compared with untreated titanium alloy, the titanium alloy after the treatment in the invention keeps excellent mechanical property and biocompatibility of the matrix, at the same time, active function group is introduced to the alloy surface, thus leading to good biological activity, the active function group covalent linkage is connected with biological functional macro molecules, thus further improving the histocompatibility and blood compatibility of implanted or interventional material.